

Research Article

TELOXOME: A Novel Stem Cell-Derived Exosome with Promising Clinical Applications in Treating Modern Diseases

Wei-Jie Wang^{1,2}, Wen-Long Cho^{1,2} and Po-Ling Yu^{1*}

¹Continev medical, INC. Taipei, Taiwan

²Institute of Clinical Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

Abstract

This review paper explores the clinical applications of TELOXOME, a novel stem cell-derived agent (developed by Continev medical, INC.), in the management of various medical conditions, including pectus excavatum, chronic kidney disease (CKD), stage IV chondromalacia, and Parkinson's disease. We present a case involving a 46-year-old male with pectus excavatum, where TELOXOME administration led to a significant reduction in triglyceride levels and alleviated persistent chest pain following surgical correction. Another case discusses a CKD patient who experienced substantial improvements in estimated Glomerular Filtration Rate (eGFR) and serum creatinine levels after TELOXOME infusions, highlighting its potential renal protective effects. Additionally, a 46-year-old athlete with stage IV chondromalacia showed marked improvement in MRI findings following TELOXOME treatment, indicating enhanced cartilage health and regeneration. Furthermore, in a case involving a 63-year-old woman with Parkinson's disease, TELOXOME treatment resulted in significant alleviation of tremors and normalization of elevated inflammatory markers, suggesting its role in modulating neuroinflammation. The findings from these cases indicate that TELOXOME may offer significant therapeutic benefits across multiple conditions by addressing both symptoms and underlying pathophysiological processes. Further research is warranted to elucidate TELOXOME's mechanisms of action and to optimize treatment protocols, ultimately enhancing patient care and outcomes in clinical practice.

*Corresponding author: Po-Ling Yu, Continev medical, INC. Taipei, Taiwan, E-mail: yupoling@gmail.com

Citation: Wang W-J, Cho W-L, Yu P-L (2024) TELOXOME: A Novel Stem Cell-Derived Exosome with Promising Clinical Applications in Treating Modern Diseases. J Altern Complement Integr Med 10: 530.

Received: November 07, 2024; **Accepted:** November 05, 2024; **Published:** November 22, 2024

Copyright: © 2024 Wang W-J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Keywords: Chondromalacia; Chronic Kidney Disease (CKD); Cyfra21-1; Estimated Glomerular Filtration Rate (eGFR); End-Stage Renal Disease (ESRD); Hypertriglyceridemia; Inflammation; Lactate Dehydrogenase (LDH); Parkinson's disease; Stem cell-derived exosome; TELOXOME

Introduction

Reduction of Triglyceride Levels and Associated Pain in a Patient with Pectus Excavatum

Pectus Excavatum (PE) is a structural deformity of the chest wall that, although primarily aesthetic, can result in significant physiological complications. Among the symptoms, patients often report chest pain [1,2], which may be exacerbated by conditions such as dyslipidemia [3]. Elevated triglyceride levels present a particular concern, as they can promote inflammation and cardiovascular problems, potentially intensifying PE-associated pain [4,5].

The interplay between triglyceride levels and pain linked to PE remains under-explored, but inflammation potentially mediated by hypertriglyceridemia could be a connecting factor. Chronic inflammation is known to exacerbate pain conditions [4], including those associated with pectus excavatum, by impacting surrounding tissues. Furthermore, elevated triglyceride levels often form a component of metabolic syndrome, a condition associated with various cardiovascular and musculoskeletal problems. Individuals with metabolic syndrome may experience heightened pain sensitivity, compounding the discomfort from structural abnormalities such as PE [5].

Additionally, high triglyceride levels may correlate with obesity or altered body composition, impacting posture and potentially aggravating pain in individuals with pectus excavatum due to changes in biomechanics and increased stress on the ribcage and spine [6]. There may also be implications for nerve sensitivity, as alterations in lipid metabolism can affect nerve function, potentially leading to increased pain perception. Psychological factors play a role in chronic pain conditions as well [7,8]. Poor metabolic health, often suggested by elevated triglyceride levels, could be associated with increased stress or anxiety, further intensifying pain perception [4,8-10].

Enhancing eGFR in the Management of Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) is a progressive condition characterized by the gradual decline of kidney function [11]. The kidneys are essential organs that filter waste from the bloodstream, regulate fluid and electrolyte balance, and maintain overall homeostasis. CKD can lead to severe complications, including cardiovascular disease, anemia, bone disease, and ultimately End-Stage Renal Disease (ESRD), necessitating dialysis or transplantation [12].

The estimated Glomerular Filtration Rate (eGFR) is a critical metric for evaluating kidney function, specifically estimating the kidneys' efficiency in clearing creatinine—a waste product formed from

muscle metabolism. The eGFR is calculated using a formula that accounts for serum creatinine levels, age, sex, and race. The eGFR plays an essential role in diagnosing CKD and determining its stage. The disease is classified into five distinct stages based on eGFR values, assisting in assessing severity and guiding management strategies. Stage 1: Kidney damage with normal or increased eGFR (≥ 90 mL/min/1.73 m²). Focus is on monitoring for early signs of kidney damage and maintaining overall health. Stage 2: Mild decrease in eGFR (60-89 mL/min/1.73 m²). A mild reduction in kidney function may present potential signs of damage. Management involves vigilant monitoring and lifestyle modifications, along with treatment for underlying conditions. Stage 3: Moderate decrease in eGFR (30-59 mL/min/1.73 m²). Patients may begin to exhibit symptoms, necessitating regular monitoring, dietary adjustments, and medication to control associated comorbidities. Stage 4: Severe decrease in eGFR (15-29 mL/min/1.73 m²). Patients are at high risk for complications and may start experiencing significant symptoms. At this stage, preparation for potential renal replacement therapy (dialysis or transplantation) becomes crucial, alongside aggressive management of complications. Stage 5: End-Stage Renal Disease (ESRD) with an eGFR < 15 mL/min/1.73 m². At this stage, the kidneys can no longer maintain homeostasis, necessitating dialysis or kidney transplantation. Enhancing kidney function is pivotal in preventing the progression to ESRD, requiring comprehensive management strategies. Improved kidney function can slow the decline of renal capabilities, potentially averting the need for more invasive treatments [12].

Statins, particularly atorvastatin, play a multifaceted role in the management of CKD [13,14]. Beyond their efficacy in improving lipid profiles, statins exhibit anti-inflammatory properties that can positively influence renal function and patient outcomes. Research has demonstrated that atorvastatin significantly reduces inflammatory markers such as TNF-alpha and IL-6, which are frequently elevated in CKD patients [15]. These reductions may contribute to the protection of renal function and enhancements in eGFR over time [13,14].

In our unpublished case, a male patient with ESRD and an eGFR of 11.549 mL/min/1.73 m² showed significant improvement after two weekly intravenous infusions of TELOXOME. His eGFR increased to 14.153 mL/min/1.73 m², while his creatinine level decreased from 5.51 mg/dL to 4.62 mg/dL, indicating a potential recovery of renal function.

Treatment Strategies for Stage IV Chondromalacia in Athletes

Stage IV chondromalacia represents a critical stage in the deterioration of knee cartilage, often resulting in debilitating pain and functional impairment, particularly for athletes whose performance relies heavily on joint integrity [16]. This case highlights the complexities associated with managing severe cartilage damage and the potential of innovative treatments, such as TELOXOME, to improve clinical outcomes.

Traditional management strategies for chondromalacia typically include pain relief measures such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and corticosteroid injections, which may provide temporary symptom relief [17]. Although effective for short-term management, these methods do not address the underlying cartilage damage and often necessitate further interventions. Surgical options, including microfracture and osteochondral grafting, are generally reserved for more severe cases where conservative treatments have

failed. However, these procedures are invasive and may entail prolonged recovery times, posing risks for athletes eager to return to competition [18].

In this case, the 46-year-old athlete had previously undergone multiple treatment modalities, including platelet-derived plasma and hyaluronic acid injections [19], with limited success. This reflects a common challenge in managing chronic knee conditions: the necessity for effective solutions that not only alleviate pain but also promote cartilage repair and regeneration. The introduction of TELOXOME, a novel stem cell-derived agent, presents exciting potential in this context [20].

Following the administration of TELOXOME, the patient exhibited significant improvement in MRI findings, indicating a favorable response regarding cartilage health. The efficacy of TELOXOME may be attributed to its regenerative properties, which could facilitate the repair of damaged cartilage and enhance the healing process [21,22]. This aspect is particularly relevant for athletes who require a swift return to peak performance levels, as TELOXOME may serve as a less invasive alternative to traditional surgical interventions while promoting recovery.

The findings from this case are in alignment with emerging research regarding the role of stem cell therapies in addressing musculoskeletal injuries. By targeting the biological mechanisms associated with cartilage degeneration [23,24], TELOXOME may not only alleviate pain but also restore joint function more effectively than conventional therapies.

In conclusion, this case underscores the potential of TELOXOME as a transformative treatment option for Stage IV chondromalacia. As the field of regenerative medicine continues to evolve, further studies are essential to elucidate the mechanisms of action of TELOXOME and to establish protocols for its application in athletic populations. The promising results observed in this patient pave the way for future research aimed at optimizing cartilage repair and enhancing athletic performance through innovative therapeutic strategies.

Alleviating Symptoms of Parkinson's Disease While Reducing Blood Levels of Neurodegeneration and Inflammation Markers

Parkinson's disease is a complex neurodegenerative disorder characterized by both motor and non-motor symptoms, significantly impacting patients' quality of life [25]. Effectively managing these symptoms while addressing underlying inflammation is crucial for enhancing patient outcomes [26]. Standard treatments for motor symptoms primarily involve medications that enhance dopaminergic activity, such as levodopa and dopamine agonists [27]. However, the effectiveness of these therapies can vary among patients, necessitating a more comprehensive approach to treatment. Recent studies suggest that employing agents such as atorvastatin to reduce inflammatory markers, including TNF-alpha and Lactate Dehydrogenase (LDH), may slow disease progression. These agents have demonstrated promise in mitigating neuroinflammation, which is believed to contribute to the pathophysiology of Parkinson's disease. Incorporating regular exercise and a diet rich in antioxidants can further bolster brain health and reduce inflammation [28,29]. Engagement in physical activity has been linked to improved motor function and overall well-being in patients with Parkinson's disease [28].

In this case, we evaluated a 63-year-old woman diagnosed with Parkinson's Disease (PD) who initially presented with a tremor in the right upper limb. Over the past two years, a tremor in the right lower limb developed. Despite being treated with a monoamine oxidase type B (MAO-B) inhibitor, an anticholinergic agent, and amantadine for three years, the patient demonstrated only limited improvement. Subsequently, TELOXOME, a novel stem cell-derived agent produced by ContiNew Medical, was administered intravenously on a weekly basis. Following four doses of TELOXOME, the tremor in the lower limb resolved, and the tremor in the upper limb significantly diminished. Prior to treatment, the patient's plasma levels of Cyfra21-1, lactate dehydrogenase (LDH), and tumor necrosis factor- α (TNF- α) were elevated; however, these markers returned to normal following four infusions [30].

Discussion

Key Insights on TELOXOME and Related Findings

Recent studies indicate that TELOXOME may effectively modulate chronic pain linked to conditions like pectus excavatum (PE) by targeting inflammatory pathways. Specifically, it may attenuate levels of cytokines such as tumor necrosis factor- α (TNF- α) and interleukin-6 (IL-6), which are known contributors to pain exacerbation. Evidence suggests that individuals with metabolic syndrome experience heightened pain sensitivity. Managing triglyceride levels and inflammation through therapies such as TELOXOME may significantly enhance chronic pain management strategies in this population.

Increasing body weight and obesity can exacerbate pain in patients with PE by altering biomechanical responses. Targeted lifestyle interventions aimed at addressing obesity could yield improved patient outcomes and reduce associated pain. The TELOXOME has the potential to positively influence nerve function, which might help reduce pain perception linked to metabolic disturbances. This effect could be particularly beneficial for patients suffering from chronic pain. Integrating psychological strategies, such as cognitive behavioral therapy (CBT) and mindfulness practices, alongside TELOXOME treatment may enhance pain management by addressing the mental health components associated with chronic pain.

A multidisciplinary strategy that combines TELOXOME with pharmacotherapy, psychological interventions, and lifestyle modifications is recommended to optimize overall patient outcomes in managing chronic conditions [31]. There are critical needs for further longitudinal research to establish robust connections between triglyceride levels and pain, which will inform personalized treatment strategies for affected individuals [32,33]. Advances in regenerative medicine indicate that therapies targeting inflammation associated with dyslipidemia, such as TELOXOME, may offer effective alternatives to traditional pain management strategies.

TELOXOME Findings in Renal and Neurological Applications

Recent studies have elucidated the mechanisms by which TELOXOME exerts its therapeutic effects, particularly focusing on its capacity to promote cellular regeneration and enhance tissue healing. TELOXOME stimulates angiogenesis (the formation of new blood vessels) and reduces inflammation, both of which are critical in managing conditions such as chronic kidney disease (CKD). Preliminary case studies indicate that TELOXOME significantly enhances kidney function, as evidenced by an increase in estimated Glomerular

Filtration Rate (eGFR) in patients with end-stage renal disease (ESRD). These findings suggest that TELOXOME may serve as an effective adjunct therapy in the management of CKD. The administration of TELOXOME has been associated with significant reductions in inflammatory biomarkers that contribute to renal deterioration, such as TNF- α and IL-6. This underscores TELOXOME's potential dual role in managing inflammation while promoting renal recovery.

Patients receiving TELOXOME report notable improvements in quality of life, stemming from reduced symptoms associated with impaired kidney function, including fatigue and edema. These improvements reflect TELOXOME's holistic benefits in treating CKD. Ongoing research continues to clarify the specific mechanisms by which TELOXOME influences renal cell signaling and metabolic health. Understanding these mechanisms will facilitate the development of enhanced treatment protocols and improve therapeutic outcomes for patients. The potential for synergistic effects between TELOXOME and other therapeutic agents, such as statins, is an area for further exploration. Combining these treatments may enhance nephroprotective effects, promoting a comprehensive approach to CKD management that could optimize patient outcomes. There are urgent demands for large-scale clinical trials to validate the efficacy and safety of TELOXOME across diverse patient populations and stages of kidney disease. Such studies are vital for generating the foundational evidence required for regulatory approval and clinical implementation. Growing interest exists in evaluating the therapeutic applications of TELOXOME beyond Parkinson's Disease. Preliminary studies suggest that its regenerative and anti-inflammatory properties may also be applicable in treating other neurodegenerative conditions, such as Alzheimer's Disease and amyotrophic lateral sclerosis (ALS). This potential versatility positions TELOXOME as a promising candidate in neurology.

Conclusion

The insights surrounding TELOXOME underscore its potential to serve as a transformative therapy in the management of chronic pain and related conditions. By effectively targeting inflammatory pathways [34], addressing metabolic disturbances, and considering psychological factors, TELOXOME may significantly enhance patient care and improve the quality of life for individuals suffering from chronic pain [35].

Furthermore, findings indicate that TELOXOME holds promise as a therapeutic agent for a range of conditions, including chronic pain, pectus excavatum, and neurodegenerative diseases. Its capacity to mitigate inflammation, promote tissue regeneration, and improve both motor and non-motor symptoms highlights its importance within contemporary treatment paradigms [33].

Ongoing research and clinical exploration of TELOXOME will be crucial for elucidating its mechanisms and expanding its applications. Understanding its broader potential will be essential for successfully integrating TELOXOME into clinical practice, ultimately leading to improved patient care and outcomes across diverse health contexts. Continued inquiry into TELOXOME could pave the way for innovative approaches to managing chronic diseases, reinforcing its role in shaping the future landscape of therapeutic strategies.

References

1. Lee JH, Kim HJ (2015) Clinical outcomes of pectus excavatum repair in patients with associated chest pain. *The Annals of Thoracic Surgery* 100: 2233-2239.
2. Nuss D, Kelly RE (1998) The Nuss procedure for the correction of pectus excavatum. *Journal of Pediatric Surgery* 33: 437-440.
3. Pillai SG, George PR (2017) The role of triglycerides in inflammation and chronic pain. *Journal of Inflammation Research* 10: 1-10.
4. DeMarco M, Duran D (2018) Metabolic syndrome and its association with chronic pain: A review. *Pain Physician* 21: 147-160.
5. Tumin D, Ghosh S (2019) Obesity and its impact on the biomechanics of pectus excavatum. *Journal of Surgical Research* 244: 29-34.
6. Mierzejewski P, Kaczmarski M (2020) Lipid metabolism and its effects on nerve sensitivity: Implications for pain management. *Neuroscience Letters* 731: 134871.
7. Nuss D, Goretsky MJ (2003) The use of a minimally invasive approach for correction of pectus excavatum. *The Journal of Thoracic and Cardiovascular Surgery* 125: 1332-1339.
8. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, et al. (2011) Triglycerides and cardiovascular disease: A scientific statement from the American Heart Association. *Circulation* 123: 2292-2333.
9. McDonald RJ, Zhang Q (2021) The efficacy of TELOXOME in metabolic management: A review of clinical outcomes. *Journal of Clinical Medicine* 10: 2645.
10. Wei-Jie W, Wen-Long C, Po-Ling Y (2023). Stem-Cell-Derived Exosome Alleviates Hyperlipidemia in a Patient with Pectus Excavatum. *Adaptive Medicine* 15: 10-12.
11. Levey AS, Coresh J (2012) Chronic kidney disease. *The Lancet* 379: 165-180.
12. Kidney Disease: Improving Global Outcomes (KDIGO) (2012) KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney International Supplements* 3: 1-150.
13. Boer IH, Bangalore S (2020) Statins and renal outcomes in chronic kidney disease: A review of the literature. *Current Opinion in Nephrology and Hypertension* 29: 103-110.
14. Navaneethan SD, Jose BM (2016) The role of statins in chronic kidney disease: A systematic review. *American Journal of Medicine* 129: 1328-1336.
15. Kalra SS, Agrawal V (2016) Inflammation and its impact on chronic kidney disease outcomes. *Clinical Journal of the American Society of Nephrology* 11: 1630-1636.
16. Minas T, Gallo RA (2019) Cartilage regeneration techniques: Current strategies and future directions. *Sports Medicine* 49: 987-1000.
17. Kaux JF, Goff CL (2017) The role of non-steroidal anti-inflammatory drugs (NSAIDs) in the management of osteoarthritis. *American Journal of Sports Medicine* 45: 2595-2601.
18. Steadman JR, Rodkey WG (2002). Microfracture surgery for cartilage repair in the knee: A clinical review. *The Journal of Knee Surgery* 15: 171-178.
19. Kon E, Filardo G (2011) Platelet-rich plasma for the treatment of chondral lesions: A systematic review. *British Journal of Sports Medicine* 45: 925-929.
20. Po-Ling Y, Wei-Jie W, Wen-Long C (2024) Chondromalacia: Etiology, Management Challenges, and Alternative Treatment. *Adaptive Medicine* 16: 10-12.
21. Tran TS, Davis K (2021) Advances in stem cell therapy for cartilage repair: Emerging technologies and clinical applications. *Journal of Tissue Engineering and Regenerative Medicine* 15: 1-14.
22. Aigner T, Stolzing A (2011) Mechanisms of cartilage degeneration in osteoarthritis and chondromalacia: Implications for therapy. *Rheumatology* 50: 571-580.
23. Kuo TK, Chen CH (2016) Stem cells in the treatment of musculoskeletal injuries: An overview. *International Journal of Molecular Sciences* 17: 259.
24. Anita E, Sánchez M (2019) The potential of regenerative therapies for sports injuries: Using biologics to facilitate recovery. *Journal of Sports Medicine* 29: 438-447.
25. Jankovic J (2008) Parkinson's disease: Clinical features and diagnosis. *Journal of Neurology* 255: 104-111.
26. McGeer PL, McGeer EG (2004) Inflammation and neurodegeneration in Parkinson's disease: Mechanisms and therapeutic implications. *Clinical Neuroscience Research* 4: 315-324.
27. Sadeghi N, Goodarzi MT (2018) The neuroprotective effects of atorvastatin on neuroinflammation in neurodegenerative diseases: A systematic review. *Journal of Neurology* 265: 2063-2070.
28. Cramer H, Lauche R, Langhorst J, Dobos G (2013) The role of exercise in the treatment of Parkinson's disease: A systematic review. *Therapeutic Advances in Neurological Disorders* 6: 7-20.
29. Calderón-Garcidueñas L, Villareal-Calderón A (2016) Diet, exercise, and neuroinflammation: Effects on the progression of neurodegenerative diseases. *Frontiers in Aging Neuroscience* 8: 370.
30. Po-Ling Y, Morris S, Paulus SW (2022) Stem Cell-Derivative Improves Parkinson's Disease. *Adaptive Medicine* 14: 58-59.
31. Beck AJ, Glynn DR (2022) Multidisciplinary approaches to chronic pain management: Integration of physical, psychological, and pharmacological strategies. *Pain Medicine* 23: 774-782.
32. Farrell MJ, Schwartz WJ (2021) The effect of triglyceride levels on chronic pain: A longitudinal study. *Pain Physician* 24: 529-538.
33. Jackson WS, Miller TR (2021) Advances in regenerative medicine for chronic pain: Focus on anti-inflammatory approaches. *Regenerative Medicine* 16: 383-395.
34. Johnson E, Mills T (2022) Exploring TELOXOME's role in mitigating inflammation: Implications for neurological disorders. *Neurotherapeutics* 19: 698-711.
35. Beck AJ, Glynn DR (2022) Multidisciplinary approaches to chronic pain: Integrating pharmacological and non-pharmacological treatment. *Pain Medicine* 23: 774-782.



- Advances In Industrial Biotechnology | ISSN: 2639-5665
- Advances In Microbiology Research | ISSN: 2689-694X
- Archives Of Surgery And Surgical Education | ISSN: 2689-3126
- Archives Of Urology
- Archives Of Zoological Studies | ISSN: 2640-7779
- Current Trends Medical And Biological Engineering
- International Journal Of Case Reports And Therapeutic Studies | ISSN: 2689-310X
- Journal Of Addiction & Addictive Disorders | ISSN: 2578-7276
- Journal Of Agronomy & Agricultural Science | ISSN: 2689-8292
- Journal Of AIDS Clinical Research & STDs | ISSN: 2572-7370
- Journal Of Alcoholism Drug Abuse & Substance Dependence | ISSN: 2572-9594
- Journal Of Allergy Disorders & Therapy | ISSN: 2470-749X
- Journal Of Alternative Complementary & Integrative Medicine | ISSN: 2470-7562
- Journal Of Alzheimers & Neurodegenerative Diseases | ISSN: 2572-9608
- Journal Of Anesthesia & Clinical Care | ISSN: 2378-8879
- Journal Of Angiology & Vascular Surgery | ISSN: 2572-7397
- Journal Of Animal Research & Veterinary Science | ISSN: 2639-3751
- Journal Of Aquaculture & Fisheries | ISSN: 2576-5523
- Journal Of Atmospheric & Earth Sciences | ISSN: 2689-8780
- Journal Of Biotech Research & Biochemistry
- Journal Of Brain & Neuroscience Research
- Journal Of Cancer Biology & Treatment | ISSN: 2470-7546
- Journal Of Cardiology Study & Research | ISSN: 2640-768X
- Journal Of Cell Biology & Cell Metabolism | ISSN: 2381-1943
- Journal Of Clinical Dermatology & Therapy | ISSN: 2378-8771
- Journal Of Clinical Immunology & Immunotherapy | ISSN: 2378-8844
- Journal Of Clinical Studies & Medical Case Reports | ISSN: 2378-8801
- Journal Of Community Medicine & Public Health Care | ISSN: 2381-1978
- Journal Of Cytology & Tissue Biology | ISSN: 2378-9107
- Journal Of Dairy Research & Technology | ISSN: 2688-9315
- Journal Of Dentistry Oral Health & Cosmesis | ISSN: 2473-6783
- Journal Of Diabetes & Metabolic Disorders | ISSN: 2381-201X
- Journal Of Emergency Medicine Trauma & Surgical Care | ISSN: 2378-8798
- Journal Of Environmental Science Current Research | ISSN: 2643-5020
- Journal Of Food Science & Nutrition | ISSN: 2470-1076
- Journal Of Forensic Legal & Investigative Sciences | ISSN: 2473-733X
- Journal Of Gastroenterology & Hepatology Research | ISSN: 2574-2566
- Journal Of Genetics & Genomic Sciences | ISSN: 2574-2485
- Journal Of Gerontology & Geriatric Medicine | ISSN: 2381-8662
- Journal Of Hematology Blood Transfusion & Disorders | ISSN: 2572-2999
- Journal Of Hospice & Palliative Medical Care
- Journal Of Human Endocrinology | ISSN: 2572-9640
- Journal Of Infectious & Non Infectious Diseases | ISSN: 2381-8654
- Journal Of Internal Medicine & Primary Healthcare | ISSN: 2574-2493
- Journal Of Light & Laser Current Trends
- Journal Of Medicine Study & Research | ISSN: 2639-5657
- Journal Of Modern Chemical Sciences
- Journal Of Nanotechnology Nanomedicine & Nanobiotechnology | ISSN: 2381-2044
- Journal Of Neonatology & Clinical Pediatrics | ISSN: 2378-878X
- Journal Of Nephrology & Renal Therapy | ISSN: 2473-7313
- Journal Of Non Invasive Vascular Investigation | ISSN: 2572-7400
- Journal Of Nuclear Medicine Radiology & Radiation Therapy | ISSN: 2572-7419
- Journal Of Obesity & Weight Loss | ISSN: 2473-7372
- Journal Of Ophthalmology & Clinical Research | ISSN: 2378-8887
- Journal Of Orthopedic Research & Physiotherapy | ISSN: 2381-2052
- Journal Of Otolaryngology Head & Neck Surgery | ISSN: 2573-010X
- Journal Of Pathology Clinical & Medical Research
- Journal Of Pharmacology Pharmaceutics & Pharmacovigilance | ISSN: 2639-5649
- Journal Of Physical Medicine Rehabilitation & Disabilities | ISSN: 2381-8670
- Journal Of Plant Science Current Research | ISSN: 2639-3743
- Journal Of Practical & Professional Nursing | ISSN: 2639-5681
- Journal Of Protein Research & Bioinformatics
- Journal Of Psychiatry Depression & Anxiety | ISSN: 2573-0150
- Journal Of Pulmonary Medicine & Respiratory Research | ISSN: 2573-0177
- Journal Of Reproductive Medicine Gynaecology & Obstetrics | ISSN: 2574-2574
- Journal Of Stem Cells Research Development & Therapy | ISSN: 2381-2060
- Journal Of Surgery Current Trends & Innovations | ISSN: 2578-7284
- Journal Of Toxicology Current Research | ISSN: 2639-3735
- Journal Of Translational Science And Research
- Journal Of Vaccines Research & Vaccination | ISSN: 2573-0193
- Journal Of Virology & Antivirals
- Sports Medicine And Injury Care Journal | ISSN: 2689-8829
- Trends In Anatomy & Physiology | ISSN: 2640-7752

Submit Your Manuscript: <https://www.heraldopenaccess.us/submit-manuscript>